bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc.
- Market cap
- $5.52M
Your view on BIAFW
Overview
What the company does, where it operates, and who runs it.
About bioAffinity Technologies, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Maria Zannes
- Headquarters
- 3300 Nacogdoches Road, San Antonio, TX, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Maria Zannes
- Headquarters
- 3300 Nacogdoches Road, San Antonio, TX, US
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for bioAffinity Technologies, Inc.. Starting points for bioAffinity Technologies, Inc.: EPS -$17.19, beta -1.05 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for bioAffinity Technologies, Inc.. Trailing twelve-month EPS for bioAffinity Technologies, Inc. stands at -$17.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | This yearYear to Dec 2026 |
|---|---|---|
| Average estimate | −$27.00 | −$121.50 |
| Lowest estimate | −$27.00 | −$121.50 |
| Highest estimate | −$27.00 | −$121.50 |
| Number of analysts | 1 | 1 |
| A year ago | $5.981 | −$129.901 |
| Growth vs a year ago | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | This yearYear to Dec 2026 |
|---|---|---|
| Average estimate | $2.22M | $7.31M |
| Lowest estimate | $2.22M | $7.31M |
| Highest estimate | $2.22M | $7.31M |
| Number of analysts | 1 | 1 |
| A year ago | $1.59M | $6.16M |
| Growth vs a year ago | +39.3% | +18.6% |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for bioAffinity Technologies, Inc.. bioAffinity Technologies, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| BTAIBioXcel Therapeutics, Inc. | Healthcare | Biotechnology | $2.3M | ||
| CCELCryo-Cell International, Inc. | Healthcare | Medical - Care Facilities | $33.5M | ||
| ECORelectroCore, Inc. | Healthcare | Medical - Devices | $40.8M | ||
| NMTCNeuroOne Medical Technologies Corporation | Healthcare | Medical - Devices | $5.9M | ||
| PRPOPrecipio, Inc. | Healthcare | Medical - Diagnostics & Research | $31.1M | ||
| RMTIRockwell Medical, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $23.5M | ||
| STRRStar Equity Holdings, Inc. | Industrials | Conglomerates | $30.7M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| SHL.AXSonic Healthcare Limited | Healthcare | ASX | — | ||
| SKHCFSonic Healthcare Limited | Healthcare | OTC | $7.9B | ||
| AAgilent Technologies, Inc. | Healthcare | NYSE | $48.0B | ||
| ABDXFAbingdon Health Plc | Healthcare | OTC | $13.3M | ||
| ACL.AXAustralian Clinical Labs Limited | Healthcare | ASX | — | ||
| ADVBAdvanced Biomed Inc. Common Stock | Healthcare | NASDAQ | $2.7M | ||
| ANPCFCellbxhealth PLC | Healthcare | OTC | $4.5M | ||
| ARYCArrayit Corporation | Healthcare | OTC | $79,348 | ||
| AVCR.VAvricore Health Inc. | Healthcare | TSXV | $3.2M | ||
| AVCRFAvricore Health Inc. | Healthcare | OTC | $6.2M | ||
| BDSXBiodesix, Inc. | Healthcare | NASDAQ | $61.5M | ||
| BDX.AXBCAL Diagnostics Limited | Healthcare | ASX | — | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by bioAffinity Technologies, Inc. executives and directors. Shares of bioAffinity Technologies, Inc. have traded between $0.06 and $0.47 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for bioAffinity Technologies, Inc.. Coverage tracks bioAffinity Technologies, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of bioAffinity Technologies, Inc.